Video
Author(s):
In this video, Eric Jonasch, MD, discusses the results from 2022 ASCO Annual Meeting abstract 4509, “Phase 1 LITESPARK-001 (MK-6482-001) study of the HIF-2α inhibitor belzutifan in advanced solid tumors: Update of the clear cell renal cell carcinoma (ccRCC) cohort with more than 3 years of total follow-up.” Jonasch is a professor in the Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center.